Pseudomonas antigens and antigen combinations

Abstract

An effective Pseudomonas aeruginosa vaccine may require one or several antigenic components, and so various antigens of P. aeruginosa are identified for use in immunisation. These polypeptides may optionally be used in combination with other nosocomial antigens.

1 . (canceled) 
     
     
         2 . An immunogenic composition comprising a PSE21-5 (PA5112) antigen and optionally one or more antigens selected from the list of: a PSE44-4 (PA3526) antigen; a PSE10-1 (PA1178) antigen; a PSE54 (PA5340) antigen; a PSE27-1 (PA0328) antigen; a PSE52-1 (PA4765) antigen; a PSE53-1 (PA5047) antigen; PSE11-3 (PA1248) antigen; a PSE41-5 (PA2407) antigen; a PSE47A-2 (PA4082); PSE5-1 (PA0595); PSE13-2 (PA1954); PSE17-1 (PA3692); PSE18-2 (PA4370); PSE20-1 (PA4735); PSE23-1 (PA3647); PSE24-1 (PA0126); PSE25-1 (PA0189); PSE26-1 (PA0274); PSE28-2 (PA0537); PSE31-2 (PA0737); PSE33-2 (PA1086); PSE42-1 (PA2793); PSE45-2 (PA3535); PSE50-1 (PA4578); PSE51-4 (PA4667); PSE19-1 (PA4710); PSE34-1 (PA1106); PSE36-3 (PA1324); PSE38-1 (PA1777). 
     
     
         3 . The composition of  claim 2 , comprising a PSE21-5 (PA5112) antigen in combination with at least one other antigen selected from the list: a PSE44-4 (PA3526) antigen; a PSE10-1 (PA1178) antigen; a PSE54 (PA5340) antigen; a PSE27-1 (PA0328) antigen; a PSE52-1 (PA4765) antigen; a PSE53-1 (PA5047) antigen; PSE11-3 (PA1248) antigen; a PSE41 (PA2407) antigen; a PSE47A-2 (PA4082); PSE5-1 (PA0595); PSE13-2 (PA1954); PSE17-1 (PA3692); PSE18-2 (PA4370); PSE20-1 (PA4735); PSE23-1 (PA3647); PSE24-1 (PA0126); PSE25-1 (PA0189); PSE26-1 (PA0274); PSE28-2 (PA0537); PSE31-2 (PA0737); PSE33-2 (PA1086); PSE42-1 (PA2793); PSE45-2 (PA3535); PSE50-1 (PA4578); PSE51-4 (PA4667); PSE19-1 (PA4710); PSE34-1 (PA1106); PSE36-3 (PA1324); PSE38-1 (PA1777). 
     
     
         4 . The composition according to  claim 3 , further comprising one or more antigens selected from the list: PilA, OprF-OprI, FliC, FliD, ExoA. 
     
     
         5 . The composition of  claim 3 , comprising at least one antigen selected from: PSE10-1 (PA1178), PSE52-1 (PA4765), PSE53-1 (PA5047) and PSE54 (PA5340). 
     
     
         6 . The composition of  claim 3 , comprising one or more antigens selected from the group consisting of: a PSE54 (PA5340) antigen; a PSE10-1 (PA1178) antigen; a PSE44-4 (PA3526) antigen; a PSE52-1(PA4765) antigen; a PSE53-1 (PA5047) antigen; a PSE27-1 (PA0328) antigen; a PSE47A-2 (PA4082) antigen; or OprF-OprI. 
     
     
         7 . The composition of  claim 2 , wherein one or more of said antigens is adsorbed to an aluminium hydroxide adjuvant. 
     
     
         8 . The composition of  claim 7 , wherein the composition includes a histidine buffer. 
     
     
         9 . The composition of  claim 2 , further comprising: one or more conjugates of (i) a  P. aeruginosa  exopolysaccharide and (ii) a carrier protein. 
     
     
         10 . The composition of  claim 2 , further comprising one or more of:
 (a) one or more conjugates of a  S. aureus  exopolysaccharide;   (b) one or more protein antigens of a  S. aureus;      (c) one or more pathogenic  E. coli  antigen/s; or   (d) one or more pathogenic  B. cenocepacia  antigen/s.   
     
     
         11 . The composition of  claim 2 , further comprising one or more of (i) a OprF-OprI antigen; (ii) a FliC antigen; (iii) a FliD antigen; and/or (iv) a PilA antigen. 
     
     
         12 . The composition according to  claim 11 , wherein the one or more antigens is a OprF-OprI antigen. 
     
     
         13 . The composition of  claim 2 , wherein the composition further comprises an adjuvant. 
     
     
         14 . A pharmaceutical composition comprising:
 (a) a polypeptide comprising an amino acid sequence having 80% or more identity to SEQ ID NO: 3 which can elicit an antibody that recognises SEQ ID NO: 3; or   (b) a polypeptide comprising amino acid sequence SEQ ID NO:38; and   optionally further comprising an amino acid sequence having 80% or more identity to any one of SEQ ID NOs: 1-2, 4-35 or SEQ ID NOs: 36-65.   
     
     
         15 . A method of raising an immune response against  Pseudomonas aeruginosa  infections in a mammal comprising administering the immunogenic composition of  claim 2  to the mammal. 
     
     
         16 . The method of  claim 15 , wherein the immune response is protective against nosocomial infections caused by  Pseudomonas aeruginosa.